Zhitong Finance App News, Le Meridien Vaccine (06660.HK) announced on August 3 that the company has independently developed a serum-free iterative rabies vaccine. It has previously submitted a marketing registration application to the State Drug Administration, and has successfully completed on-site verification. In the first half of this year, Le Meridien Honors received the CDE supplementary information notice. As a routine process during the vaccine review stage, the company has completed the data in accordance with the review opinions and submitted supplementary data to the CDE, and significant progress has been made in the registration and application process for the serum-free iterative rabies vaccine.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.